Clinical Intergroup – Clinical Studies
Primary studies
MCL Younger
Efficacy of 6 courses CHOP plus Rituximab followed by myeloablative
radiochemotherapy and autologous stem cell transplantation
versus alternating courses of 3x CHOP and 3x DHAP plus Rituximab
followed by a high dose ARA-C containing myeloablative regimen and
autologous stem cell transplantation
Achtung: In dieser Studie wird nicht mehr randomisiert, sondern nur noch dem CHOP/AraC -Arm zugewiesen.
Further information
MCL Elderly
Efficacy of maintenance therapy with rituximab
after induction chemotherapy (R-CHOP vs. R-FC)
for elderly patients with mantle cell lymphoma
not suitable for stem cell transplantation
Further information
Rezidivstudien
Zevalin-Study
Efficacy and safety of 90Y-ibritumomab tiuxetan
in patients with
refractory or relapsed mantle cell lymphoma
after / not appropriate
for autologous stem cell transplantation
Attention: This study is closed!
Further information
R-HAD-Studie (MCL 2005-01)
EFFICACY AND SAFETY OF RITUXIMAB, HIGH-DOSE ARA-C
AND DEXAMETHASONE (R-HAD) ALONE OR IN COMBINATION
WITH BORTEZOMIB IN PATIENTS WITH RELAPSED OR
REFRACTORY MANTLE CELL LYMPHOMA
Further information